Anthropic launches Claude Science, an AI workbench for scientific research
Anthropic launched Claude Science on June 30, 2026, an AI workbench designed to accelerate scientific research, particularly in drug discovery and computational biology. The tool integrates over 60 curated scientific databases and specialized toolkits (genomics, proteomics, chemistry, cheminformatics) into a single environment, letting researchers work in one place instead of bouncing between PubMed, Jupyter, R terminals, and proprietary lab tools. Claude Science runs on existing Claude models, including Opus 4.8—not a new specialized model.
The workbench includes a verification agent that flags incorrect citations and calculations before results are committed to manuscripts, addressing a key pain point in AI-assisted scientific writing. It runs locally on macOS/Linux or connects to HPC clusters, ensuring sensitive lab data never leaves institutional infrastructure. Anthropic is backing up to 50 research projects with up to $30,000 in compute credits each (applications open through July 15), positioning the product ahead of OpenAI's GPT-Rosalind in terms of accessibility.
For architects, this signals Anthropic's pivot toward vertical SaaS products targeting pharma and biotech ahead of its 2026 IPO. The move creates recurring revenue from high-margin enterprise workflows. Novartis CEO Vas Narasimhan (on Anthropic's board) estimated AI tools like Claude Science could cut drug approval timelines from 12 years to 7-8 years, pointing to the real-world impact on pharma workflows and the compelling business case for vertical AI products.
Sources
- Primary source
- technology.org
“Claude Science integrates 60+ scientific databases and tools; runs locally on macOS/Linux or HPC; verification agent flags citation errors”
- statnews.com
“Dario Amodei: Claude Science will do for life sciences what Claude Code did for programming”
- finance.yahoo.com
“Anthropic backing 50 projects with up to $30k credits; applications open through July 15; helps diversify revenue ahead of IPO”